King's College London

Research portal

The Pharmacological Potential of Adenosine A 2A Receptor Antagonists for Treating Parkinson's Disease

Research output: Contribution to journalArticlepeer-review

Akihisa Mori, Jiang-Fan Chen, Shinichi Uchida, Cecile Durlach, Shelby M King, Peter Jenner

Original languageEnglish
Article number2366
JournalMolecules (Basel, Switzerland)
Issue number7
Early online date6 Apr 2022
Accepted/In press31 Mar 2022
E-pub ahead of print6 Apr 2022
Published6 Apr 2022

Bibliographical note

Funding Information: Acknowledgments: Medical writing assistance (referencing and editing) was provided by Anita Chadha-Patel and Elizabeth Hocking of ACP Clinical Communications, Ltd. (Hertfordshire, UK) and funded by Kyowa Kirin, Inc. (Bedminster, NJ, USA). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.


King's Authors


The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson's disease (PD). The selective A2A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454